Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
Articles
Psychedelics Convergence in 2022: Crisis Meets Opportunity
The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, "crisis" meets "opportunity".
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Health Canada’s SAP Amendments: A Game-Changer For Psychedelic Medicine In Canada?
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
The next big trend in mental health treatments? Psychedelic therapy.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
BREAKING: Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
Value, Growth and Opportunity: Why Psychedelic Stocks Are Poised To Rebound In 2022
After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.
Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy
Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.